Cefoxitin: Difference between revisions
(Replace manual dosing with dynamic SMW tables (Adult + Pediatric)) |
(Restore original dosing content alongside dynamic SMW tables) |
||
| Line 7: | Line 7: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*1-2g IV q6-8h | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Cefoxitin]] [[Has Population::Adult]] | {{#ask: [[Has DrugName::Cefoxitin]] [[Has Population::Adult]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*<3 months old: Safety & efficacy not established | |||
*>3 months old: 80-160 mg/kg/day IV divided q4-6hr; higher dosages should be used for more severe or serious infections | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Cefoxitin]] [[Has Population::Pediatric]] | {{#ask: [[Has DrugName::Cefoxitin]] [[Has Population::Pediatric]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
Latest revision as of 02:38, 20 March 2026
General
- Type: 2nd generation cephalosporin
- Dosage Forms: powder for injection
- Dosage Strengths: 1g, 2g, 10g
- Route of Administration: IV
- Common Trade Names: Mefoxin
Adult Dosing
- 1-2g IV q6-8h
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Mammalian bites | 1g IV q8hrs (25mg/kg q6hrs) | Severe mammalian bite infection |
| Pelvic inflammatory disease | 2g IV q6hr | Inpatient |
| Pelvic inflammatory disease | 2g IM x1 plus Probenecid 1g PO | Outpatient alternative |
| Postpartum endometritis | 2g IV q6hrs | <48hrs postpartum; combined with Doxycycline |
Pediatric Dosing
- <3 months old: Safety & efficacy not established
- >3 months old: 80-160 mg/kg/day IV divided q4-6hr; higher dosages should be used for more severe or serious infections
Indications by Disease
Special Populations
- Pregnancy: Category B
- Lactation: Minimal excretion in breast milk, limited data on affect to infant
- Renal Dosing
- CrCl 30-50 mL/min: 1-2 g q8-12hr
- CrCl 10-30 mL/min: 1-2 g q12-24hr
- CrCl 5-9 mL/min: 500 mg-1 g q24-28hr
- CrCl <5 mL/min: 500 mg-1 g q24-48hr
- Hepatic Dosing: not defined
Contraindications
- Allergy to class/drug
- Neonates
Adverse Reactions
Serious
Common
- Diarrhea
- Anemia, thrombocytopenia, transient leukopenia
- Elevated Cr/BUN
- Elevated LFTs
Pharmacology
- Half-life: 45-60 min
- Metabolism:
- Excretion: Unchanged in urine (85%)
- Mechanism of Action: Inhibits bacterial cell wall synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014